Skip to main content
Top
Published in: BMC Medicine 1/2018

Open Access 01-12-2018 | Opinion

Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation

Authors: Didier Samuel, Audrey Coilly

Published in: BMC Medicine | Issue 1/2018

Login to get access

Abstract

Background

The results of liver transplantation are excellent, with survival rates of over 90 and 80% at 1 and 5 years, respectively. The success of liver transplantation has led to an increase in the indications for liver transplantation. Generally, priorities are given to cirrhotic patients with a high Model for End-Stage Liver Disease (MELD) score on the principle of the sickest first and to patients with hepatocellular carcinoma (HCC) on the principle of priority points according to the size and number of nodules of HCC. These criteria can lead to a ‘competition’ on the waiting list between the above patients and those who are cirrhotic and have an intermediate MELD score or with life-threatening liver diseases not well described by the MELD score. For this latter group of patients, ‘MELD exception’ points can be arbitrarily given.

Discussion

The management of patients on the waiting list is of prime importance to avoid death and drop out from the waiting list as well as to improve post-transplant survival rates. For the more severe cases who may swiftly access liver transplantation, it is essential to rapidly determine whether liver transplantation is indeed indicated, and to organise a fast workup ahead of this. It is also essential to identify the ideal timing for liver transplantation in order to minimise mortality rates. For patients with HCC, a bridge therapy is frequently required to avoid progression of HCC and to maintain patients within the criteria of liver transplantation as well as to reduce the risk of post-transplant recurrence of HCC. For patients with cirrhosis and intermediate MELD score, waiting time can exceed 1 year; therefore, regular follow-up and management are essential to maintain the patient alive on the waiting list and to achieve a good survival after liver transplantation.

Conclusion

There is a diversity of patients on the waiting list for transplantation and equity should be preserved between those with cirrhosis of high and intermediate severity and those with HCC. The management of patients on the waiting list is an essential component of the success of liver transplantation.
Literature
1.
go back to reference EASL. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64:433–85.CrossRef EASL. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64:433–85.CrossRef
3.
go back to reference Clinical Practice EASL Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–81. Clinical Practice EASL Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–81.
4.
go back to reference Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease score and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMed Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease score and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMed
5.
go back to reference Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.CrossRefPubMedPubMedCentral Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.CrossRefPubMedPubMedCentral
6.
go back to reference Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease score optimize prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011;140:1952–60.CrossRefPubMedPubMedCentral Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease score optimize prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011;140:1952–60.CrossRefPubMedPubMedCentral
7.
go back to reference Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Mortality on the liver transplant waiting list: unintended policy consequences and model for end stage liver disease (MELD) inflation. Hepatology. 2015;61:285–91.CrossRefPubMed Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Mortality on the liver transplant waiting list: unintended policy consequences and model for end stage liver disease (MELD) inflation. Hepatology. 2015;61:285–91.CrossRefPubMed
8.
go back to reference Petrowsky H, Rana A, Kaldas FM, Sharma A, Hong JC, Agopian VG, et al. Liver transplantation in highest acuity recipients. Identifying factors for avoiding futility. Ann Surg. 2014;259:1186–94.CrossRefPubMed Petrowsky H, Rana A, Kaldas FM, Sharma A, Hong JC, Agopian VG, et al. Liver transplantation in highest acuity recipients. Identifying factors for avoiding futility. Ann Surg. 2014;259:1186–94.CrossRefPubMed
9.
go back to reference Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–800.CrossRefPubMed Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–800.CrossRefPubMed
10.
go back to reference Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute on chronic liver failure: syndrome and effects on prognosis. Hepatology. 2015;62:243–52.CrossRefPubMed Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute on chronic liver failure: syndrome and effects on prognosis. Hepatology. 2015;62:243–52.CrossRefPubMed
11.
go back to reference Sharma P, Schaubel DE, Gong Q, Guidinguer M, Merion RM. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Hepatology. 2012;55:192–8.CrossRefPubMed Sharma P, Schaubel DE, Gong Q, Guidinguer M, Merion RM. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Hepatology. 2012;55:192–8.CrossRefPubMed
12.
go back to reference Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–15.CrossRefPubMed Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–15.CrossRefPubMed
13.
go back to reference Nadim MK, DiNorcia J, Ji L, Groshen S, Levistsky J, Sung R, et al. Inequity in organ allocatin for patients awaiting liver transplantation: rationale for uncapping the model for end stage liver disease. J Hepatol. 2017;67:517–25.CrossRefPubMed Nadim MK, DiNorcia J, Ji L, Groshen S, Levistsky J, Sung R, et al. Inequity in organ allocatin for patients awaiting liver transplantation: rationale for uncapping the model for end stage liver disease. J Hepatol. 2017;67:517–25.CrossRefPubMed
14.
go back to reference Weil D, Levesque E, McPhall M, Cavalazzi R, Theocaridou E, Cholongitas E, et al. Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis. Ann Int Care. 2017;7:33.CrossRef Weil D, Levesque E, McPhall M, Cavalazzi R, Theocaridou E, Cholongitas E, et al. Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis. Ann Int Care. 2017;7:33.CrossRef
15.
go back to reference Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113:235–42.CrossRefPubMed Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113:235–42.CrossRefPubMed
16.
go back to reference Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B, Clavien PA. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 2015;148:307–23.CrossRefPubMed Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B, Clavien PA. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 2015;148:307–23.CrossRefPubMed
17.
go back to reference Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, Samuel D, Saliba F. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol. 2012;56(1):95–102.CrossRefPubMed Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, Samuel D, Saliba F. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol. 2012;56(1):95–102.CrossRefPubMed
18.
go back to reference Saliba F, Ichaï P, Levesque E, Samuel D. Cirrhotic patients in the ICU: prognostic markers and outcome. Curr Opin Crit Care. 2013;19(2):154–60.CrossRefPubMed Saliba F, Ichaï P, Levesque E, Samuel D. Cirrhotic patients in the ICU: prognostic markers and outcome. Curr Opin Crit Care. 2013;19(2):154–60.CrossRefPubMed
19.
go back to reference Levesque E, Saliba F, Ichaï P, Samuel D. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. J Hepatol. 2014;60:570–8.CrossRefPubMed Levesque E, Saliba F, Ichaï P, Samuel D. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. J Hepatol. 2014;60:570–8.CrossRefPubMed
20.
go back to reference Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis. 2016;16:735–45.CrossRefPubMedPubMedCentral Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis. 2016;16:735–45.CrossRefPubMedPubMedCentral
21.
go back to reference Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–31.CrossRefPubMed Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–31.CrossRefPubMed
22.
go back to reference Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97.CrossRefPubMed Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97.CrossRefPubMed
23.
go back to reference Debette-Gratien M, Tabouret T, Antonini M-T, Dalmay F, Carrier P, Legros R, et al. Personalized adapted physical activity before liver transplantation: acceptability and results. Transplantation. 2015;99(1):145–50.CrossRefPubMed Debette-Gratien M, Tabouret T, Antonini M-T, Dalmay F, Carrier P, Legros R, et al. Personalized adapted physical activity before liver transplantation: acceptability and results. Transplantation. 2015;99(1):145–50.CrossRefPubMed
24.
go back to reference Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.CrossRefPubMed Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.CrossRefPubMed
25.
go back to reference Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of akphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129–37.CrossRefPubMed Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of akphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129–37.CrossRefPubMed
26.
go back to reference Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRefPubMed Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRefPubMed
27.
go back to reference Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefPubMed Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefPubMed
28.
go back to reference Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefPubMed Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefPubMed
30.
go back to reference Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Non-alcoholic steatohepatitis is the second leading etiology of liver diseases among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Non-alcoholic steatohepatitis is the second leading etiology of liver diseases among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.CrossRefPubMed
Metadata
Title
Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation
Authors
Didier Samuel
Audrey Coilly
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2018
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-018-1110-y

Other articles of this Issue 1/2018

BMC Medicine 1/2018 Go to the issue